Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-Peptidic, GP IIb/IIIa Receptor Antagonist Following Multiple Oral Administrations of a Prodrug Form

Thrombosis and Haemostasis - Germany
doi 10.1055/s-0037-1614238
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Georg Thieme Verlag KG

Related search

Pharmacokinetics and Pharmacodynamics of Tecarfarin, a Novel Vitamin K Antagonist Oral Anticoagulant

Thrombosis and Haemostasis
Hematology
2017English

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan

Clinical Pharmacokinetics
Pharmacology
2015English

Pharmacokinetics, Safety and Tolerability of L-3-N-Butylphthalide Tablet After Single and Multiple Oral Administrations in Healthy Chinese Volunteers

Brazilian Journal of Pharmaceutical Sciences
ToxicologyPharmaceuticsPharmacology
2015English

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

Clinical Cancer Research
Cancer ResearchOncology
2009English

Pharmacokinetics and Pharmacodynamics of Verapamil Following Sublingual and Oral Administration to Healthy Volunteers.

British Journal of Clinical Pharmacology
Pharmacology
1992English

Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese and Non-Asian Male Subjects

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Off-Target Effects of Glycoprotein IIb/IIIa Receptor Inhibitors

Cardiology Journal
MedicineCardiovascular MedicineCardiology
2014English

Oral Administration of the GnRH Antagonist Acyline, in a GIPET®-enhanced Tablet Form, Acutely Suppresses Serum Testosterone in Normal Men: Single-Dose Pharmacokinetics and Pharmacodynamics

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2009English

Pharmacokinetics, Safety and Tolerability of Bencycloquidium Bromide, a Novel Selective Muscarinic M1/M3 Receptor Antagonist, After Single and Multiple Intranasal Doses in Healthy Chinese Subjects

Drugs in R and D
Pharmacology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy